✦ LIBER ✦

9242 Pharmacogenetic factors in metabolism, transport and toxicity of cytarabine treatment in patients with AML

✍ Scribed by Seeringer, A.; Yi-Jing, H.; Schlenk, R.; Doehner, K.; Doehner, H.; Kirchheiner, J.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Idarubicin in combination with cytarabin

✍ Pogliani, E.M.; Baldicchi, L.; Pioltelli, P.; Miccolis, I.R.; Mangiagalli, M.; C 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 91 KB

SNP analyses in cytarabine metabolizing

✍ Mahlknecht, U; Dransfeld, C-L; Bulut, N; Kramer, M; Thiede, C; Ehninger, G; Scha 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 180 KB

Treatment of Hypertension and Other Card

✍ Suzuki, Takeki; Homma, Shunichi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 149 KB

Treatment of therapy-related acute myelo

✍ Hiro Tatetsu; Fumihiko Matsuno; Noritaka Takatsu; Hirosada Miyake; Koyu Hoshino; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 86 KB

Toxicities Following Treatment with Bisp

✍ Gartrell, Benjamin A.; Coleman, Robert E.; Fizazi, Karim; Miller, Kurt; Saad, Fr 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 351 KB

Effect of Metabolic Syndrome Factors and

✍ Jeffrey B. Rosen; Christie M. Ballantyne; Scott M. Grundy; Willa A. Hsueh; Hans- 📂 Article 📅 2009 🏛 Elsevier 🌐 English ⚖ 264 KB